Literature DB >> 19265263

Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells.

Kazushige Mori1, Kaori Fujimoto-Ouchi, Etsuro Onuma, Mariko Noguchi, Yasushi Shimonaka, Hideyuki Yasuno, Takashi Nishimura.   

Abstract

We established models of cancer-related anemia in mice from subcutaneous inoculation of two IL-6-producing cancer cell lines, human lung cancer cell line LC-06-JCK and murine colon26 clone 5 colon cancer cells. In both models, elevated levels of IL-6 were detected in sera and hemoglobin levels significantly decreased compared with non-tumor-bearing mice. In the LC-06-JCK model, serum albumin levels also decreased with elevated levels of human IL-6 in sera. On the other hand, serum levels of EPO increased, although anemia developed and did not improve. The development of cancer-related anemia was prevented by the administration of a rat anti-mouse IL-6 receptor antibody, MR16-1, in the LC-06-JCK model. It is therefore suggested that IL-6 causes anemia independent of a reduction in EPO levels. Our preclinical models should be useful for exploring new modalities for the treatment of cancer-related anemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265263     DOI: 10.2220/biomedres.30.47

Source DB:  PubMed          Journal:  Biomed Res        ISSN: 0388-6107            Impact factor:   1.203


  6 in total

1.  AP-VAS 2012 case report: a case of ANCA-negative pauci-immune crescentic glomerulonephritis associated with IL-6-producing adenosquamous cell carcinoma of the lung.

Authors:  Takashi Morikawa; Atsuhiro Yoshida; Shinya Kobayashi; Mikiko Shibata; Masahiro Hamada; Masatsugu Kishida; Chizuko Kitabayashi; Haruko Daga; Yoshio Konishi; Koji Takeda; Masahito Imanishi
Journal:  CEN Case Rep       Date:  2013-03-14

2.  In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.

Authors:  DE-Jun Guo; Jia-Shan Han; Yan-Song Li; Zeng-Shan Liu; Shi-Ying Lu; Hong-Lin Ren
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

3.  Genetic analysis of intestinal polyp development in Collaborative Cross mice carrying the Apc (Min/+) mutation.

Authors:  Alexandra Dorman; Daria Baer; Ian Tomlinson; Richard Mott; Fuad A Iraqi
Journal:  BMC Genet       Date:  2016-02-19       Impact factor: 2.797

4.  Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer.

Authors:  Katsutoshi Ando; Fumiyuki Takahashi; Motoyasu Kato; Norihiro Kaneko; Tokuhide Doi; Yuichiro Ohe; Fumiaki Koizumi; Kazuto Nishio; Kazuhisa Takahashi
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

5.  Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells.

Authors:  Mariko Noguchi-Sasaki; Yusuke Sasaki; Yasushi Shimonaka; Kazushige Mori; Kaori Fujimoto-Ouchi
Journal:  BMC Cancer       Date:  2016-04-11       Impact factor: 4.430

6.  The diagnostic and prognostic value of interleukin-6 in patients with soft tissue sarcomas.

Authors:  Tomohito Hagi; Tomoki Nakamura; Takahiro Iino; Takao Matsubara; Kunihiro Asanuma; Akihiko Matsumine; Akihiro Sudo
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.